U.S. Markets closed
  • S&P Futures

    3,659.25
    +36.00 (+0.99%)
     
  • Dow Futures

    29,913.00
    +284.00 (+0.96%)
     
  • Nasdaq Futures

    12,396.25
    +119.25 (+0.97%)
     
  • Russell 2000 Futures

    1,844.20
    +24.10 (+1.32%)
     
  • Crude Oil

    45.01
    -0.33 (-0.73%)
     
  • Gold

    1,787.80
    +6.90 (+0.39%)
     
  • Silver

    22.95
    +0.36 (+1.60%)
     
  • EUR/USD

    1.1962
    +0.0027 (+0.2273%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3358
    +0.0026 (+0.1950%)
     
  • USD/JPY

    104.4040
    +0.0800 (+0.0767%)
     
  • BTC-USD

    19,540.85
    +30.96 (+0.16%)
     
  • CMC Crypto 200

    383.35
    +18.75 (+5.14%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting

Conference Call and Webcast to Be Held Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT

LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET / 1:30 pm GMT to review clinical data presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.

Conference Call Information
To listen to the webcast and view the accompanying slide presentation, please go to https://www.autolus.com/investor-relations/news-events/events.

The call may also be accessed by dialing 866-679-5407 (U.S.) or 409-217-8320 (international) and referencing conference ID 9796038.

After the conference call, a replay will be available for one week. To access the replay, please dial 855-859-2056 (U.S.) or 404-537-3406 (international) and enter conference ID 9796038.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Investor and media contact:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com

UK:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com